Celltrion, Inc. (068270.KS) stock analysis

In our weekly check, Celltrion, Inc. is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 19 pass, warnings: 3, red flags: 3.

About Celltrion, Inc.

Celltrion, Inc. is a Healthcare company (Biotechnology) based in South Korea, listed on KSC as 068270.KS.

What our checks show for 068270.KS

Red flags

• Analysts expect the net margin to shrink by 3.2 points from today's 32.2%.
• The stock has fallen as much as 69% from a peak. Would you have held through that?
• The share count grew by 61.8% in 2 years: each shareholder owns a smaller slice.

Warning signs

• Operating cash flow is only 0.6x net profit: part of the reported profit does not arrive as cash.
• The price swings a lot: 41.4% annual volatility. Expect large ups and downs.
• Return on capital (ROCE) is only 8.3%.

Strengths

• Net debt is only 1.4x a year of EBITDA: the balance sheet has room.
• Operating profit covers interest 16.5 times over.
• The net margin rose by 1.6 points over 5 years, to 32.2%.
• The gross margin is 60.7% and has risen by 2.3 points: pricing power is holding.
• Analysts expect earnings per share to grow about 11% a year over the next years.
• Analysts expect revenue to grow about 16.5% a year over the next years.

Similar companies

207940.KS · 196170.KQ

Questions

What grade does Celltrion, Inc. (068270.KS) have?

In our weekly check, Celltrion, Inc. is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 19 pass, warnings: 3, red flags: 3. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of 068270.KS stock?

This week's biggest flags for Celltrion, Inc.: Margins expected to shrink, Deep past fall, Share dilution. In total 6 of 25 checks show a warning or a red flag.

What does Celltrion, Inc. do?

Celltrion, Inc. is a Healthcare company (Biotechnology) based in South Korea, listed on KSC as 068270.KS.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-24

Open the full analysis